Author

L. Picton

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:host-pathogen & immune response· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

K. C. Garcia· 2 shared L. Su· 2 shared A. C. Huang· 1 shared C. Blaj· 1 shared C. J. Nicolai· 1 shared C. K. Garcia· 1 shared C. O. Ndubaku· 1 shared D. H. Raulet· 1 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

K. C. Garcia

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Enhanced STAT5a activation rewires exhausted CD8 T cells during chronic stimulation to acquire a hybrid durable effector like state

J. C. Beltra, M. S. Abdel-Hakeem, S. Manne, Z. Zhang, H. Huang, M. Kurachi, L. Su, L. Picton, Y. Muroyama, V. Casella, Y. J. Huang, J. R. Giles, D. Mathew, J. Belman, M. Klapholz, , J. E. Wherry

This study shows that enhancing STAT5a activation in exhausted CD8 T cells rewires their epigenetic state to become a hybrid durable effector-like population with improved tumor control.

bioRxiv · Oct 3, 2022 · PreprintImmunology

Induced CD45 Proximity Potentiates Natural Killer Cell Receptor Antagonism

J. Ren, Y. Jo, L. Picton, L. Su, D. Raulet, K. C. Garcia

This study shows that CD45-linked NKR antagonists enhance NK and T cell activity more than traditional antibodies, revealing potential for improved cancer immunotherapies.

bioRxiv · Jun 27, 2022Bioengineering

Powerful synergistic effects of a STING agonist and an IL-2 superkine in cancer immunotherapy against MHC I-deficient and MHC I+ tumors

N. K. Wolf, C. Blaj, L. Picton, G. Snyder, L. Zhang, C. J. Nicolai, C. O. Ndubaku, S. M. McWhirter, K. C. Garcia, D. H. Raulet

The paper combines a STING agonist and an IL-2 superkine to enhance cancer immunotherapy, showing efficacy against both MHC I-deficient and MHC I+ tumors.

bioRxiv · Nov 2, 2021 · PreprintImmunology